تحلیل اختیاری محصول
با اجازه شما، از تحلیلهای محدود و حریمخصوصیمحور استفاده میکنیم تا مسیرهای پژوهشی مؤثر را بشناسیم. از ردیاب تبلیغاتی یا بازپخش نشست استفاده نمیکنیم. این انتخاب را میتوانید در تنظیمات تغییر دهید. بخوانید سیاست حفظ حریم خصوصی.
Danaher Corporation's published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $157.3B | |
|---|---|---|
| Revenue (ttm) | 25.6B | |
| Net income (ttm) | 4.3B | |
| EPS (ttm) | $6.10 | |
| Shares out | 703.5M | |
| P/E (trailing) | 38.3x | |
| P/E (forward) | 23.8x | |
| Dividend | $1.60 (0.68%) | |
| Volume | 2,725,890 | |
| Beta | 0.80 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $24.80B | $26.64B | $23.89B | $23.88B | $24.57B | -0.2% |
| Gross profit | $15.24B | $16.19B | $14.03B | $14.21B | $14.52B | -1.2% |
| Operating income | $6.38B | $7.54B | $5.20B | $4.86B | $4.69B | -7.4% |
| Net income | $6.43B | $7.21B | $4.76B | $3.90B | $3.61B | -13.4% |
| EPS (diluted) | $8.61 | $9.66 | $6.38 | $5.29 | $5.05 | -12.5% |
| EBITDA | $10.01B | $9.49B | $5.20B | $7.28B | $6.95B | -8.7% |
| R&D | $1.50B | $1.53B | $1.50B | $1.58B | $1.60B | +1.6% |
| SG&A | $6.82B | $7.12B | $7.33B | $7.76B | $8.24B | +4.8% |
Recent company headlines from major financial publishers.
Consolidated core revenue expands at 3%-4% in FY2026 and reaccelerates to 8.0% in FY2027 as customer batch manufacturing schedules normalize and deferred chromatography resin shipments deliver,. Operating margins progress from 19.09% in FY2025 to 26.5% in FY2026 and reach 28.5% over the forecast horizon,. Free cash flow conversion remains above 100%, funding debt service and regular share repurchases.
Rapid absorption of bioprocessing inventory leads to accelerated commercial batch manufacturing and new greenfield quoting. Specialty diagnostics maintain high single-digit momentum driven by DxI 9000 and Cepheid non-respiratory assays, while China hospital procurement rebounds. Operating margins expand ahead of schedule, driving strong double-digit earnings growth.
| Ke ↓ / g → | 2.5% | 2.8% | 3.0% | 3.3% | 3.5% |
|---|---|---|---|---|---|
| 7.5% | $207 | $212 | $217 | $224 | $231 |
| 8.0% | $192 | $196 | $201 | $205 | $211 |
| 8.5% | $180 | $183 | $187 | $190 | $194 |
| 9.0% | $170 | $172 | $175 | $178 | $181 |
| 9.5% | $161 | $163 | $165 | $167 | $170 |
Upcoming earnings date and setup when available.
رتبهای که نسخهٔ پژوهشی منتشرشدهٔ هر ماه داشت. رتبه قیمت در تاریخ تحلیل را با ارزش منصفانه مقایسه میکند و سابقهای از درستی یا نادرستی ارزیابی نیست.
| سال | دی | بهمن | اسفند | فروردین | اردیبهشت | خرداد | تیر | مرداد | شهریور | مهر | آبان | آذر |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
